Furthermore, in vitro treatment with ibrutinib or acalabrutinib improves CAR-T cell effector function in prolonged stimulation assays, while in vivo administration of ibrutinib or acalabrutinib improves CAR-T cell-mediated clearance of CD19+ tumor and prolongs the survival of tumor-bearing mice (Table 1; Qin et al., 2020). This evidence concerns the gene CD19 and neoplasm.